Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
A Rational Account of Categorization Based on Information Theory
arXiv:2603.29895v1 Announce Type: new Abstract: We present a new theory of categorization based on an information-theoretic rational analysis. To evaluate this theory, we investigate how well it can account for key findings from classic categorization experiments conducted by Hayes-Roth and Hayes-Roth (1977), Medin and Schaffer (1978), and Smith and Minda (1998). We find that it explains the human categorization behavior at least as well (or better) than the independent cue and context models (
-
Nature Biotechnology - Issue - nature.com science feeds
-
Mirror-enhanced 4Pi-SMLM with one objective enables isotropic nanoscale imaging
Nature Biotechnology, Published online: 31 March 2026; doi:10.1038/s41587-026-03083-7Single-molecule 4Pi microscopy is simplified and made accessible by using a single objective.
Mirror-enhanced 4Pi-SMLM with one objective enables isotropic nanoscale imaging
Nature Biotechnology, Published online: 31 March 2026; doi:10.1038/s41587-026-03083-7
Single-molecule 4Pi microscopy is simplified and made accessible by using a single objective.-
Omics In Lung
-
A monocyte-centered framework for predicting immunochemotherapy efficacy in lung squamous cell carcinoma patients
EMBO Mol Med. 2026 Mar 30. doi: 10.1038/s44321-026-00410-y. Online ahead of print.ABSTRACTLung cancer is the leading cause of cancer-related mortality worldwide, with lung squamous cell carcinoma (LUSC) comprising 20-30% of cases. Immunochemotherapy (IC) is the standard first-line treatment for advanced LUSC, yet reliable predictors of therapeutic response remain unavailable. Using single-cell multi-omics profiling of paired pre- and post-treatment tumor and blood samples, we observed that patie
A monocyte-centered framework for predicting immunochemotherapy efficacy in lung squamous cell carcinoma patients
EMBO Mol Med. 2026 Mar 30. doi: 10.1038/s44321-026-00410-y. Online ahead of print.
ABSTRACT
Lung cancer is the leading cause of cancer-related mortality worldwide, with lung squamous cell carcinoma (LUSC) comprising 20-30% of cases. Immunochemotherapy (IC) is the standard first-line treatment for advanced LUSC, yet reliable predictors of therapeutic response remain unavailable. Using single-cell multi-omics profiling of paired pre- and post-treatment tumor and blood samples, we observed that patients responding to IC exhibited significantly higher baseline levels of peripheral blood monocytes, tumor-infiltrating classical monocytes, and APOBEC3A+ monocytes across both compartments compared with non-responders. These associations were independently validated in additional cohorts using routine complete blood count testing and multiplex immunofluorescence analysis of native tumor tissues. Our findings reveal monocyte-related parameters as clinically accessible indicators that link systemic immunity with the tumor microenvironment and hold promise for predicting IC responsiveness in patients with LUSC.
PMID:41912871 | DOI:10.1038/s44321-026-00410-y
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
A monocyte-centered framework for predicting immunochemotherapy efficacy in lung squamous cell carcinoma patients
EMBO Mol Med. 2026 Mar 30. doi: 10.1038/s44321-026-00410-y. Online ahead of print.ABSTRACTLung cancer is the leading cause of cancer-related mortality worldwide, with lung squamous cell carcinoma (LUSC) comprising 20-30% of cases. Immunochemotherapy (IC) is the standard first-line treatment for advanced LUSC, yet reliable predictors of therapeutic response remain unavailable. Using single-cell multi-omics profiling of paired pre- and post-treatment tumor and blood samples, we observed that patie
A monocyte-centered framework for predicting immunochemotherapy efficacy in lung squamous cell carcinoma patients
EMBO Mol Med. 2026 Mar 30. doi: 10.1038/s44321-026-00410-y. Online ahead of print.
ABSTRACT
Lung cancer is the leading cause of cancer-related mortality worldwide, with lung squamous cell carcinoma (LUSC) comprising 20-30% of cases. Immunochemotherapy (IC) is the standard first-line treatment for advanced LUSC, yet reliable predictors of therapeutic response remain unavailable. Using single-cell multi-omics profiling of paired pre- and post-treatment tumor and blood samples, we observed that patients responding to IC exhibited significantly higher baseline levels of peripheral blood monocytes, tumor-infiltrating classical monocytes, and APOBEC3A+ monocytes across both compartments compared with non-responders. These associations were independently validated in additional cohorts using routine complete blood count testing and multiplex immunofluorescence analysis of native tumor tissues. Our findings reveal monocyte-related parameters as clinically accessible indicators that link systemic immunity with the tumor microenvironment and hold promise for predicting IC responsiveness in patients with LUSC.
PMID:41912871 | DOI:10.1038/s44321-026-00410-y